NEKTAR THERAPEUTICS (NKTR)
US6402681083 - Common Stock
ChartMill assigns a Buy % Consensus number of 75% to NKTR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.18. This target is 360.67% above the current price.
NKTR was analyzed by 12 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about NKTR.
In the last month the buy percentage rose by 23 points. So the trust of analysts is improving.
NKTR was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-04 | Piper Sandler | Initiate | Overweight |
| 2024-03-06 | Jefferies | Maintains | Hold -> Hold |
| 2023-11-20 | JP Morgan | Reiterate | Underweight |
| 2023-11-09 | TD Cowen | Upgrade | Market Perform -> Outperform |
| 2023-08-07 | Mizuho | Reiterate | Neutral |
| 2023-05-10 | Jefferies | Upgrade | Underperform -> Hold |
| 2023-03-06 | Oppenheimer | Maintains | Perform |
| 2023-02-27 | Goldman Sachs | Maintains | Sell |
| 2023-02-24 | SVB Leerink | Maintains | Market Perform |
| 2023-02-24 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-08-08 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-04-18 | Mizuho | Maintains | Neutral |
| 2022-04-18 | SVB Leerink | Maintains | Market Perform |
| 2022-04-18 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2022-03-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2021-11-08 | Benchmark | Upgrade | Hold -> Buy |
| 2021-11-08 | SVB Leerink | Maintains | Market Perform |
| 2021-11-05 | Oppenheimer | Maintains | Perform |
| 2021-09-10 | B of A Securities | Initiate | Neutral |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
| 2021-06-28 | Stifel | Upgrade | Hold -> Buy |
| 2021-05-10 | SVB Leerink | Maintains | Market Perform |
| 2021-04-06 | SVB Leerink | Maintains | Market Perform |
| 2021-02-22 | Benchmark | Downgrade | Buy -> Hold |